Publications Archive
Hedgehog
American Society of Clinical Oncology Gastrointestinal Cancers Symposium
- Richards, D.A., Stephenson, J., Wolpin, B.M., Becerra, C., Hamm, J.T., Messersmith, W.A., Devens, S., Cushing, J., Skliris, G., Kutok, J., Schmalbach, T., Fuchs, C.S. A Phase 1b Trial of IPI-926 (Saridegib), a Hedgehog Pathway Inhibitor, Plus Gemcitabine in Patients with Metastatic Pancreatic Cancer.
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications
- Coco, J., West, K., McGovern, K., Read, M., MacDougall, J., Fritz, C. IPI-926 delays metastatic spread in an experimental model of pancreatic liver metastases.
Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy
- Campbell, V.T., Coco, J., Deyneko, I., Proctor, J., West, K., McGovern, K., MacDougall, J. The Hedgehog inhibitor IPI-926 increases tumor perfusion and enhances drug delivery in a preclinical pancreatic cancer xenograft model.
American Society of Clinical Oncology
- Rudin, C.M., Jimeno, A., Miller, Jr., W.H., Eigl, B., Gettinger, S., Chang, A., Faia, K., Sweeney, J., Loewen, G., Ross, R., Weiss, G.J. A Phase 1 Study of IPI-926, a Novel Hedgehog Pathway Inhibitor, in Patients with Advanced or Metastatic Solid Tumors.
- Stephenson, J., Richards, D., Wolpin, B., Becerra, C., Hamm, J., Messersmith, W., Devens, S., Cushing, J., Goddard, J., Schmalbach, T., Fuchs, C.S. A Phase 1b Study Evaluating IPI-926 in Combination with Gemcitabine in Patients with Metastatic Pancreatic Cancer.
American Association for Cancer Research
- Campbell, V.T, Nadesan, P.P., Wang, Y., Whetstone, H., Robison, K., White, K., McGovern, K., Read, M., Alman, B.A., Wunder, J.S. Direct targeting of the Hedgehog pathway in primary chondrosarcoma xenografts with the Smoothened inhibitor IPI-926.
- Read, M.A. Direct Targeting of Tumor Cells with Smoothened Inhibitor IPI-926he Hh inhibitor IPI-926.
- Tremblay, M., Austad, B.C., Adams, J., Behnke, M.L., Castro, A.C., Campbell, M.J., Genov, D., Ferguson, J., Foley, M.A., Grogan, M.J., Grenier, L., Hague, A., Helble, J.C., Lane, B., Lescarbeau, A., Lo, P., Lory, C., Mann, D., Nair, S.J., Peluso, S., Porter, J.R., Yu, L., Charette, A.B. Development of a Multi-kilogram Synthetic Route to IPI-926, A Novel Hedgehog Pathway Antagonist for the Treatment of Malignant Diseases.
Public Library of Science
- Lin, T.L., Wang, Q.H., Brown, P., Peacock, C., Merchant, A.A., Brennan, S., Jones, E., McGovern, K., Watkins, D.N., Sakamoto, K.M., Matsui, W. Self-Renewal of Acute Lymphocytic Leukemia Cells Is Limited by the Hedgehog Pathway Inhibitors Cyclopamine and IPI-926.
European Society for Molecular Oncology
- Rudin, C.M., Weiss, G.J., Chang, A., Gettinger, S., Miller, W.H., Eigl, B., Savage, A., Loewen, G., Ross, R., Jimeno, A. A Phase 1 Study of IPI-926, an Inhibitor of the Hedgehog Pathway, in Patients with Advanced or Metastatic Solid Tumors.
American Association for Cancer Research
- Travaglione, V., Deyneko, I., Proctor, J., White, K., McGovern, K., Trujillo, A., Voelker, F., Ci, S., Lolkema, M., Tuveson, D., MacDougall, J. The Hh inhibitor IPI-926 enhances tumor perfusion and nab-paclitaxel activity in a pancreatic xenograft model.
- Mandley, E., White, K., Faia, K., Travaglione, V., Read, M., McGovern, K., MacDougall, J. The Hh inhibitor IPI-926 delays tumor re-growth of a non-small cell lung cancer xenograft model following treatment with an EGFR targeted tyrosine kinase inhibitor.
- Proctor, J., Travaglione, V., Deyneko, I., White, K., Read, M., Ross, R., McGovern, K., Vessella, R., MacDougall, J. Hedgehog Signaling in Castration Resistant Prostate Cancer.
American Association for Cancer Research
- Villavicencia, E., Khanna, P., Ditzler, S., Pullar, B., Hansen, S., Read, M., Faia, K., Hatton, B., Knoblaugh, S., Randolph-Habecker, J., LeBlanc, M., Shaw, D., Friedman, S., McGovern, K., Olson, J. Activity of the Hh pathway inhibitor IPI-926 in a mouse model of medulloblastoma.
- Travaglione, V., Faia, K., Conley, J., Frank, N., Proctor, J., White, K., Osswalt, M., Deyneko, I., MacDougall, J., Peacock, C., Watkins, D.N., McGovern, K., Read., M. Induction of tumor-derived hedgehog ligand by chemotherapy.
Journal of Medicinal Chemistry
- Tremblay, Martin, et al. Discovery of a Potent and Orally Active Hedgehog Pathway (IPI-926). Journal of Medicinal Chemistry, 52(14).
Science
- Olive, Kenneth P., et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science, 2009. Available from Sciencexpress. http://www.scienceexpress.org.
Society of Gynecological Oncologists Annual Meeting
- Growdon, W.M., McCann, C.R., Curley, M., Friel A.M., Mandley, E., Ferguson, J., Foster, R., MacDougal, J., Rueda, B.R. Hedgehog pathway inhibitor cyclopamine suppresses Gli1 expression and inhibits serous ovarian cancer xenograft growth.
American Association for Cancer Research
- Pink, M., Proctor, J., Briggs, K., MacDougall, J., Whitebread, N., Tremblay, M.R., Grogan, M., Palombella, V., Castro, A., Adams, J., Read, M., Corcoran-Schwartz, I.M., Harcke, T., Eberhart, C.G., Watkins, D. N., Sydor, J.. Activity of IPI-926, a potent HH pathway inhibitor, in a novel model of medulloblastoma derived from Ptch/HIC +/- mice.
- Travaglione, V., Peacock, C., MacDougall, J., McGovern, K., Cushing, J., Yu, L., Trudeau, M., Palombella, V., Adams, J., Hierman, J., Rhodes, J., Devereux, W., Watkins, D.N. A novel Hh pathway inhibitor, IPI-926, delays recurrence post-chemotherapy in a primary human SCLC xenograft model.
Hsp90
American Society of Clinical Oncology
- Riely, G.J., Gettinger, S.N., Stoller, R.G., Gabrail, N.Y., Dy, G.K., Weiss, G.J., Tunkey, C., Skliris, G., Strychor, S., Dunbar, J., DeLucia, D., Ross, R.W., Gray, J.E. Safety and Activity of IPI-504 (retaspimycin hydrochloride) and Docetaxel in Pretreated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC).
Oncogene
- Normant, E., Paez, G., West, K.A., Lim, A.R., Slocum, K.L., Tunkey, C., McDougall, J., Wylie, A.A., Robison, K., Caliri, K., Palombella, V.J., Fritz, C.C. The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models.
Journal of Biological Chemistry
- Tillotson, B., Slocum, K., Coco, J., Whitebread, N., Thomas, B., West, K.A., MacDougall, J., Ge, J., Ali, J.A., Palombella, V.J., Normant, E., Adams, J., Fritz, C.C. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.
Journal of Clinical Oncology
- Sequist, L.V., Gettinger, G., Senzer, N.N., Martins, R.G., Jänne, P.A., Lilenbaum, R., Gray, J.E., Iafrate, A.J., Katayama, R., Hafeez, N., Sweeney, J., Walker, J.R., Fritz, C., Ross, R.W., Grayzel, D., Engelman, J.A., Borger, D.R., Paez, G., Natale, R. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.
American Society for Clinical Oncology
- Sequist, L., Natale, R., Senzer, N., Martins, R., Lilenbaum, R., Gray, J., Borger, D., Lim, A., Paez, G., Grayzel, D., Gettinger, S. Association between Anaplastic Lymphoma Kinase rearrangements (rALK) and the clinical activity of IPI-504(retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC).
Current Opinion in Chemical Biology
- Porter, J.R., Fritz, C.C., Depew, K.M. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
Targeted Therapies of the Treatment of Lung Cancer
- Sequist, L. V. IPI-504: A Novel Hsp90 Inhibitor.
American Society for Clinical Oncology
- Sequist, L., Natale, R., Gettinger, S., Senzer, N., Martins, R., Lilenbaum, R., Gray, J., Janne, P., Samuel, T., Harper, H., Walker, J., Sweeney, J., Ross, R., Grayzel, D., Lynch, T. Interim Results from a Phase 2 Trial of IPI-504 (retaspimycin hydrochloride), a Novel Hsp90 Inhibitor, in Patients with Relapsed and/or Refractory Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Stratified by EGFR Mutation Status.
Interim Results from a Phase 1b Trial of IPI-504 (retaspimycin hydrochloride), a Novel Hsp90 Inhibitor, in Combination with Docetaxel.
American Association for Cancer Research
- Tillotson, B., Coco, J., Whitebread, N., West, K., Slocum, K., Thomas, B., Ge, J., Ali, J., Normant, E., Hoyt, J., MacDougall, J., Sydor., J., Palombella, V., Adams, J., Fritz, C. A novel pharmacodynamic assay to measure Hsp90 target occupancy by the small molecule inhibitors IPI-504 and IPI-493 in tumors.
European Organisation for Research and Treatment of Cancer
- Fritz, C., Ge, J., Hafez, N., Tillotson, B., Depew, K., Coco, J., Basuki, J., Lim, A., Patterson, J., Porter, J., Palombella, V., and Normant, E. Comparison of the cellular and biochemical properties of ansamycin and non-ansamycin based Hsp90 inhibitors.
- Lee., J., Grenier, L., Holson, E., Slocum, K., Coco, J., Ge, J., Normant, E., Hoyt, J., Lim, A., Cushing, J., Sydor, J., and Wright, J. IPI-493, a potent, orally bioavailable Hsp90 inhibitor of the ansamycin class. EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics”
European Organisation for Research and Treatment of Cancer
- Sequist, L., Janne, P., Sweeney, J., Walker, J., Grayzel, D., Lynch, T. Phase 1/2 Trial of the Novel Hsp90 Inhibitor, IPI-504, in Patients with Relapsed and/or Refractory Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Stratified by EGFR Mutation Status. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, B79